Immune function in childhood cancer survivors: a Children's Oncology Group review

Affiliations

¹ Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: greg.guilcher@ahs.ca.
² Pediatric Hematology and Oncology, Advocate Children's Hospital, Oak Lawn, IL, USA.
³ Department of Dermatology, Harvard Medical School, Boston, MA, USA.
⁴ Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁵ Medical College of Wisconsin, Milwaukee, WI, USA.
⁶ Department of Pediatrics, University of Colorado, Aurora, CO, USA; Center for Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, USA.
⁷ Section of Pediatric Oncology and BMT, Alberta Children's Hospital, Calgary, AB, Canada.
⁸ School of Paediatrics and Child Health, University of Western Australia, Nedland, WA, Australia; Department of Oncology, Haematology, Blood and Marrow Transplantation, Child and Adolescent Health Services, Perth Children's Hospital, Nedland, WA, Australia.
⁹ Division of Hematology and Oncology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
¹⁰ Department of Pediatrics, Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Palo Alto, CA, USA.
¹¹ Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; Children's Hospital Los Angeles, Cancer and Blood Disease Institute, Los Angeles, CA, USA.
¹² Fred Hutchinson Cancer Research Center, Clinical Research and Public Health Sciences Divisions, Seattle, WA, USA.

PMID: 33600774
PMCID: PMC8725381
DOI: 10.1016/S2352-4642(20)30312-6

Review

Immune function in childhood cancer survivors: a Children's Oncology Group review

Gregory M T Guilcher et al. Lancet Child Adolesc Health. 2021 Apr.

. 2021 Apr;5(4):284-294.

doi: 10.1016/S2352-4642(20)30312-6. Epub 2021 Feb 16.

Authors

Affiliations

¹ Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada; Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. Electronic address: greg.guilcher@ahs.ca.
² Pediatric Hematology and Oncology, Advocate Children's Hospital, Oak Lawn, IL, USA.
³ Department of Dermatology, Harvard Medical School, Boston, MA, USA.
⁴ Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
⁵ Medical College of Wisconsin, Milwaukee, WI, USA.
⁶ Department of Pediatrics, University of Colorado, Aurora, CO, USA; Center for Cancer and Blood Disorders, Children's Hospital of Colorado, Aurora, CO, USA.
⁷ Section of Pediatric Oncology and BMT, Alberta Children's Hospital, Calgary, AB, Canada.
⁸ School of Paediatrics and Child Health, University of Western Australia, Nedland, WA, Australia; Department of Oncology, Haematology, Blood and Marrow Transplantation, Child and Adolescent Health Services, Perth Children's Hospital, Nedland, WA, Australia.
⁹ Division of Hematology and Oncology, Department of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
¹⁰ Department of Pediatrics, Stem Cell Transplantation and Regenerative Medicine, Stanford School of Medicine, Palo Alto, CA, USA.
¹¹ Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA; Children's Hospital Los Angeles, Cancer and Blood Disease Institute, Los Angeles, CA, USA.
¹² Fred Hutchinson Cancer Research Center, Clinical Research and Public Health Sciences Divisions, Seattle, WA, USA.

PMID: 33600774
PMCID: PMC8725381
DOI: 10.1016/S2352-4642(20)30312-6

Abstract

Childhood cancer and its treatment often impact the haematopoietic and lymphatic systems, with immunological consequences. Immunological assessments are not routinely included in surveillance guidelines for most survivors of childhood cancer, although a robust body of literature describes immunological outcomes, testing recommendations, and revaccination guidelines after allogeneic haematopoietic cell transplantation. Survivorship care providers might not fully consider the impaired recovery of a child's immune system after cancer treatment if the child has not undergone haematopoietic cell transplantation. We did a scoping review to collate the existing literature describing immune function after childhood cancer therapy, including both standard-dose chemotherapy and high-dose chemotherapy with haematopoietic cell rescue. This Review aims to summarise: the principles of immunology and testing of immune function; the body of literature describing immunological outcomes after childhood cancer therapy, with an emphasis on the risk of infection, when is testing indicated, and preventive strategies; and knowledge gaps and opportunities for future research.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interests

GMTG received funding from Jazz Pharmaceuticals to attend the 2017 American Society of Hematology Annual Meeting. LR, JTH, NAMW, LA, HE, WP, SR, TS, AJS, KW and EW have no conflicts of interest to disclose.

References

1. Surveillance, Epidemiology, and End Results Program. Section 28: Childhood Cancer by Site, Incidence, Survival and Mortality. National Cancer Institute. Published 2019. Available at: https://seer.cancer.gov/csr/1975_2016/results_merged/sect_28_childhood_c.... Accessed August 22, 2019.
1. Kremer LCM, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer 2013;60:543–9. - PMC - PubMed
1. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572–82. - PubMed
1. Santiago R, Vairy S, Sinnett D, Krajinovic M, Bittencourt H. Novel therapy for childhood acute lymphoblastic leukemia. Expert Opin Pharmacother 2017;18:1081–99. - PubMed
1. Wayne AS, Shin-Kashiyama E, Sposto R, Gaynon P. Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL): overview and introduction to the proceedings of the 2016 TACL investigator meeting. Pediatr Hematol Oncol 2017;34:349–54. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immune function in childhood cancer survivors: a Children's Oncology Group review

Affiliations

Immune function in childhood cancer survivors: a Children's Oncology Group review

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical